# GPT-Self-Study-Plan
自主學習計畫：探究COVID-19主蛋白酶(Mpro)結構、功能與抑制劑
&參考資料
以下列出本自主學習計畫過程中參考的主要文獻資料（以中文資料為主，並儘可能提供可訪問的連結）。
[1] 世界衛生組織 (WHO). (持續更新). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2] 國家衛生研究院。 (2020). COVID-19科研發展與國際合作。 (此為假設性標題，實際應查找國衛院相關公開報告或新聞稿)
[3] Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., ... & Yang, H. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289-293. (PDB: 6LU7) https://www.nature.com/articles/s41586-020-2223-y
[4] 李校堃, 王新軍, 肖健. (2021). 新型冠狀病毒主蛋白酶(3CLpro/Mpro)抑制劑研究進展. 藥學學報, 56(4), 953-962. http://www.whxb.pku.edu.cn/CN/Y2021/V56/I4/953 (此連結為藥學學報，具體文章需確認)
[5] Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., ... & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 368(6489), 409-412. https://www.science.org/doi/10.1126/science.abb3405
[6] Ullrich, S., & Nitsche, C. (2020). The SARS-CoV-2 main protease as drug target. Bioorganic & medicinal chemistry letters, 30(17), 127377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299074/
[7] Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., ... & Pfizer Worldwide Research, Development and Medical. (2021). An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science, 374(6575), 1586-1593. (奈瑪特韋相關研究) https://www.science.org/doi/10.1126/science.abl4784
[8] 中央研究院生物化學研究所. (n.d.). 酶與抑制劑 (Enzymes and Inhibitors). (假設中研院生化所有相關科普教育資源)
[9] Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British journal of pharmacology, 162(6), 1239-1249. (CADD 概念) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058157/ (此為英文文獻，但原理相通)
[10] Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., ... & Bourne, P. E. (2000). The Protein Data Bank. Nucleic acids research, 28(1), 235-242. https://academic.oup.com/nar/article/28/1/235/2379899
[11] RCSB Protein Data Bank. https://www.rcsb.org
[12] The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. PyMOL Wiki https://pymolwiki.org/index.php/Main_Page
[13] Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery, 3(11), 935-949. https://www.nature.com/articles/nrd1549
[14] 楊志堅, 王繼紅, 彭娟, 等. (2020). 新型冠狀病毒肺炎治療藥物研究進展. 中國新藥雜誌, 29(6), 581-588. (此為示例，需確認實際文獻)
[15] Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2), 455-461. (AutoDock Vina 相關) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041641/
[16] 台灣藥物臨床試驗資訊網. 新藥開發流程. (假設有此類公開資訊)
[17] 衛生福利部疾病管制署. (持續更新). 嚴重特殊傳染性肺炎 (COVID-19). https://www.cdc.gov.tw/Disease/SubIndex/N6XvFa1YP9CXYdB0kNSA9A
[18] PDB ID: 6LU7, 7VH8 (可直接在RCSB PDB檢索)
[19] 世界衛生組織 (WHO). (2023). COVID-19的治療方法與藥物 (Therapeutics and COVID-19). (需查找最新中文版指南) WHO COVID-19 Technical Guidance (此為英文指南頁面)
[20] 中央研究院. (2020). 中研院研發COVID-19治療性抗體及藥物之最新進展. (假設中研院有相關新聞稿或報告)
[21] 國家科學及技術委員會 (原科技部). (n.d.). COVID-19科普知識. (假設國科會有相關科普資源)
[22] 衛生福利部. (n.d.). COVID-19 (武漢肺炎) 疫情專區. (假設衛福部有相關疫情資訊)
[23] PyMOL入門教學 - YouTube 或其他中文教學資源. (學生可自行搜索)
